Clinical Trial Participants of Polivy: A Breakdown by Age
H1: Introduction to Polivy and Its Clinical Trials
Polivy, also known as polatuzumab vedotin-piiq, is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL). Developed by Genentech, a member of the Roche Group, Polivy has shown promising results in clinical trials, particularly in patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies.
H2: Overview of Polivy's Clinical Trials
Polivy's clinical trials have been conducted globally, involving patients from various age groups. The trials have aimed to evaluate the efficacy and safety of Polivy in combination with other therapies, such as bendamustine and rituximab, in patients with DLBCL.
H3: Age Distribution of Clinical Trial Participants
According to the clinical trial data, the age distribution of participants in Polivy's trials is as follows:
* H4: Age 65 and Older: A significant proportion of participants in Polivy's trials were aged 65 and older. In one of the trials, 44% of participants were in this age group. This is not surprising, given that NHL is more common in older adults.
* H4: Age 55-64: The next largest age group was participants aged 55-64, who accounted for 31% of the trial population.
* H4: Age 45-54: Participants aged 45-54 made up 16% of the trial population.
* H4: Age 35-44: The youngest age group in the trials was participants aged 35-44, who accounted for 9% of the trial population.
* H4: Age 18-34: The smallest age group in the trials was participants aged 18-34, who accounted for 1% of the trial population.
H2: Demographics of Clinical Trial Participants
In addition to age, the clinical trials also collected data on other demographics, including:
* H3: Sex: The majority of participants in Polivy's trials were male (63%), while 37% were female.
* H3: Ethnicity: The trials included participants from diverse ethnic backgrounds, with the majority being White (73%), followed by Asian (14%), Black or African American (6%), and Hispanic or Latino (4%).
* H3: Performance Status: The trials also assessed the performance status of participants, with 55% having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, indicating good performance status.
H2: Safety and Efficacy of Polivy in Clinical Trials
The clinical trials of Polivy have demonstrated its safety and efficacy in patients with DLBCL. The most common adverse reactions reported in the trials were:
* H3: Neutropenia: Neutropenia was the most common adverse reaction, reported in 73% of participants.
* H3: Thrombocytopenia: Thrombocytopenia was reported in 44% of participants.
* H3: Anemia: Anemia was reported in 36% of participants.
* H3: Fatigue: Fatigue was reported in 34% of participants.
H2: Conclusion
In conclusion, the clinical trials of Polivy have involved participants from various age groups, with the majority being aged 65 and older. The trials have demonstrated the safety and efficacy of Polivy in patients with DLBCL, particularly in those who have received at least two prior therapies.
H1: Key Takeaways
* Polivy's clinical trials have involved participants from various age groups, with the majority being aged 65 and older.
* The trials have demonstrated the safety and efficacy of Polivy in patients with DLBCL.
* The most common adverse reactions reported in the trials were neutropenia, thrombocytopenia, anemia, and fatigue.
H1: FAQs
1. Q: What is Polivy?
A: Polivy is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL).
2. Q: What are the most common adverse reactions reported in Polivy's clinical trials?
A: The most common adverse reactions reported in the trials were neutropenia, thrombocytopenia, anemia, and fatigue.
3. Q: Who are the clinical trial participants of Polivy?
A: The clinical trial participants of Polivy are patients with DLBCL who have received at least two prior therapies.
4. Q: What is the age distribution of Polivy's clinical trial participants?
A: The age distribution of participants in Polivy's trials is as follows: 44% aged 65 and older, 31% aged 55-64, 16% aged 45-54, 9% aged 35-44, and 1% aged 18-34.
5. Q: What is the safety and efficacy of Polivy in clinical trials?
A: The clinical trials of Polivy have demonstrated its safety and efficacy in patients with DLBCL.
Sources:
1. DrugPatentWatch.com: A database that provides information on pharmaceutical patents, including those for Polivy.
2. Genentech: The developer of Polivy, a member of the Roche Group.
3. ClinicalTrials.gov: A database that provides information on clinical trials, including those for Polivy.
4. National Cancer Institute: A government agency that provides information on cancer, including non-Hodgkin lymphoma.
5. European Medicines Agency: A regulatory agency that provides information on medicines, including Polivy.